Eisai to cut R&D, even as it boosts its sales operation

Japanese drugmaker Eisai said in October it would add 200 sales jobs to help its partner Arena ($ARNA) with marketing of its weight-loss drug Belviq. Its R&D operations are not so lucky; the company is cutting them, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world. FierceBiotech reports that it will move its small-molecule research work done in Andover to R&D facilities in Japan and India. Development work on large-molecule products that was being done in the facility north of Boston will go to its R&D facility in Exton, PA. Story | More

 

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.